
Biotech investing is down, but some VC firms are bucking the trend
Venture capital firm Omega Funds closed a $647 million fund this month dedicated to supporting life sciences biotechs, bucking an industry trend that’s seen a swift downturn in investing since the high-on-the-hog landscape of only five years ago. In fact, …